2,710.00
+7.34%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About GlaxoSmithKline Pharmaceuticals
Its shares trade on NSE under the ticker GLAXO.NS. It has been listed since 3 November 1994. In the fiscal year to 31 March 2026, it reported revenue of ₹38.22bn and net income of ₹10.36bn. At that date it held total assets of ₹43.24bn and shareholders' equity of ₹22.67bn.
GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company is headquartered in Mumbai, Maharashtra. The firm is engaged in the business of manufacturing, distributing, and trading in pharmaceuticals. The company manufactures medicinal substances used in the manufacture of pharmaceuticals, such as antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts, and esters; glycosides and vegetable alkaloids, and chemically pure sugar. The company offers a range of prescription medicines, vaccines, and consumer healthcare products. Its medicine portfolio includes Adartrel, Bactroban, Combodart, and Duodart. Its vaccines portfolio includes Ambirix, Cervarix, Fendrix, and Havrix. The Company’s products include Betamethasone, Potassium Clavulanate with Amoxycillin and Pneumococcal Polysaccharide and Conjugate Vaccine. Its oral health products include Sensodyne, parodontax and Polident. Its manufacturing unit is located at Nashik.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Nov 1994
- Employees
- 3,840
- Website
- india-pharma.gsk.com ↗
Leadership
Pay as last reported
- Ms. Renu KarnadNon-Executive Chairman of the Board₹3.3m
- Mr. Juby ChandyChief Financial Officer, Whole Time Director, since 2022₹65.6m
- Mr. Chinmay SharmaExecutive Vice President of Human Resources
- Ms. S. ChoudharyExecutive Vice President - Regulatory Affairs
- Mr. Carson DaltonExecutive Vice President, Communications and Government Affairs
- Mr. Ransom D'SouzaExecutive Vice President - Communications and Government Affairs
- Dr. Shalini MenonExecutive Vice President - Medical Affairs
- Mr. Shourov MukherjeeExecutive Vice President - Adult Vaccines
- Mr. Amit PandeyExecutive Vice President - Legal
- Mr. Upendra SinghExecutive Vice President - General Medicines
- Mr. Ritesh ManchandaVice President - Customer Supply Chain
- Ms. Sharmishta MitraVice President - Paediatric Vaccines
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 63
- Environment
- 76
- Social
- 79
- Governance
- 35
- Direct emissions (scope 1)
- 774.32 t
- Energy emissions (scope 2)
- 9,957.92 t
- Women in the workforce
- 13.57%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- GlaxoSmithKline Pharmaceuticals Ltd is a leading pharmaceutical company globally, benefiting from its strong brand reputation, extensive product portfolio, and research and development capabilities. The company has a diversified revenue stream, with a focus on high-demand therapeutic areas such as respiratory, vaccines, and oncology. GSK's strong global presence and well-established distribution networks enable it to reach a wide consumer base and increase market share. Additionally, the company has a long history of successful mergers and acquisitions, contributing to its overall strength in the industry.
Weaknesses
- Despite its strengths, GlaxoSmithKline Pharmaceuticals Ltd faces certain weaknesses. The company has experienced declining sales in some key markets due to generic competition and patent expirations. GSK has faced criticism for its pricing strategies and ethical controversies in the past, which has affected its brand reputation. Furthermore, its heavy reliance on a few blockbuster drugs poses a risk to its revenue stream, as any setbacks or regulatory issues can significantly impact the company's financial performance.
Opportunities
- GlaxoSmithKline Pharmaceuticals Ltd has ample opportunities to capitalise on market trends and advancements in the healthcare industry. The rising demand for healthcare products and services, especially in emerging markets, presents an opportunity for GSK to expand its market reach and increase sales. The company can further invest in developing innovative drugs, leveraging its strong research and development capabilities, to address unmet medical needs. Collaborations and partnerships with other healthcare organizations, as well as digital transformation, can also open new avenues for growth.
Threats
- There are several external threats that GlaxoSmithKline Pharmaceuticals Ltd should be aware of. Intense competition from other pharmaceutical companies, both established players and emerging market entrants, poses a threat to GSK's market share. Increasing regulatory scrutiny and changing healthcare policies can impact the company's operations and profitability. Moreover, the potential threats of counterfeit drugs, global economic uncertainties, and geopolitical issues in key markets could disrupt GSK's supply chain and have adverse effects on its business performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.